Back to Journals » Drug Design, Development and Therapy » Volume 5

Corrigendum

Authors Paller CJ, Antonarakis E

Published 21 March 2011 Volume 2011:5 Pages 183—184

DOI https://doi.org/10.2147/DDDT.S19759


Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Drug Design, Development and Therapy. 2011;5:117–124.

The drug Jevtana was incorrectly named Jentava in Table 4.

Original Article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]